Fas gene promoter −670 polymorphism (A/G) is associated with cervical carcinogenesis

Ueda, Masatsugu; Hung, Yao Ching; Terai, Yoshito; Yamaguchi, Hiroyuki; Saito, Junko; Nunobiki, Osamu; Noda, Sadamu; Ueki, Minoru

doi:10.1016/j.ygyno.2005.04.001

Cited by 43 publications

(28 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our previous study showed that the FAS À670 A>G polymorphism was associated with an increased risk of lung cancer (20), and a similar association was reported with cervical cancer in a Japanese population (21). Both the FAS À1377 G>A and FAS À1377 A/À670 A haplotype were also found to be associated with risk of acute myeloid leukemia (14).…”

mentioning

confidence: 59%

Polymorphisms of FAS and FAS Ligand Genes Involved in the Death Pathway and Risk and Progression of Squamous Cell Carcinoma of the Head and Neck

Zhang¹,

Wang²,

Sturgis³

et al. 2006

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: Alteration of the FAS/FAS ligand (FASLG) pathway regulating cell death may lead to cancer development, but the effects of functional promoter polymorphisms of the FAS and FASLG genes on risk of squamous cell carcinoma of the head and neck (SCCHN) are unknown. Design: We genotyped the FAS À1377 G>A, FAS À670 A>G, FASLG À844 C>T, and FASLG IVS2nt À124 A>G polymorphisms in 721case patients with SCCHN and 1,234 cancer-free nonĤ ispanic White control subjects frequency-matched by age and sex. Multivariate logistic regression was used to assess the adjusted odds ratios (OR) and 95% confidence intervals (CI). Results: Compared with the FAS À1377 GG and À670 AA genotypes, the FAS À1377 AA and À670 (GG + AG) genotypes were associated with an increased risk of SCCHN (OR, 2.23; 95% CI, 1.07-4.64 and OR, 1.24; 95% CI, 1.01-1.52, respectively), whereas no risk of SCCHN was associated with any of the FASLG genotypes. When we used the combined FAS À1377 (GG + AG)/ À670 AA genotypes as the reference, we found that the individuals carrying the FAS À1377 AA/ À670 (GG + AG) had the highest risk (OR, 2.69; 95% CI, 1.24-5.83), whereas individuals carrying genotypes other than FAS À1377 (GG + AG)/À670 AA had a higher risk of SCCHN (OR, 1.24; 95% CI, 1.01-1.52). Furthermore, the elevated risk was particularly evident for pharyngeal cancer with the larger tumors without regional lymph metastasis (OR, 1.77; 95% CI, 1.07-2.94). Conclusions:The FAS (but not FASLG) polymorphisms seem to contribute to risk of developing SCCHN, particularly the pharyngeal cancer in non^HispanicWhites. However, potential selection bias warrants future population-based studies to verify the findings.

show abstract

mentioning

confidence: 59%

Polymorphisms of FAS and FAS Ligand Genes Involved in the Death Pathway and Risk and Progression of Squamous Cell Carcinoma of the Head and Neck

Zhang¹,

Wang²,

Sturgis³

et al. 2006

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

“…Although evidence of an association between FAS/FASL polymorphisms and cervical cancer risk has been reported, the findings remain controversial (11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22). Therefore, we performed a meta-analysis of all published studies on the association between the FAS/FASL polymorphisms and cervical cancer.…”

Section: Introductionmentioning

confidence: 99%

Lack of association between the FAS/FASL polymorphisms and cervical cancer risk: A meta-analysis

Pan

2013

Biomedical Reports

View full text Add to dashboard Cite

Abstract. FAS/FASL gene promoter polymorphisms are associated with cervical cancer risk, however, results from previous studies have been conflicting. To obtain a more precise estimation of the association between these polymorphisms and cancer risk, a meta-analysis was performed. All eligible studies up to November 1st, 2012, concerning FAS-670 A/G, FAS-1377 G/A and FASL-844 T/C polymorphisms and cervical cancer risk, were collected from the following electronic databases: PubMed, Excerpta Medica Database and Chinese Biomedical Literature Database. The odds ratio (OR) and 95% confidence interval (95% CI) were used to assess the strength of the association via the additive, codominant, dominant and recessive models. In total, 10 publications with 11 case-control studies (10 on FAS-670 A/G, 5 on FAS-1377 G/A and 6 on FASL-844 T/C polymorphisms) were included in this meta-analysis. No association between FAS-670 A/G, FAS-1377 G/A and FASL-844 T/C polymorphisms and cervical cancer susceptibility for all the genetic models was identified. Following stratification of the studies by ethnicity or source of controls, similar results were obtained. In conclusion, our findings showed that the FAS-670 A/G, FAS-1377 G/A and FASL-844 T/C polymorphisms are not associated with cervical cancer risk. Future studies with larger sample sizes are required to further evaluate these associations.

show abstract

“…Previous studies, including the 10 studies that we included in the present meta-analysis, were conducted to estimate the incidence of cervical carcinogenesis in association with the FAS-670 polymorphism; however, a consensus was not reached (13,(23)(24)(25)(26)(27)(28)(29)(30)(31). Zhang et al (32) conducted a meta-analysis on FAS promoter polymorphisms and cancer risk, but failed to demonstrate a significant association with FAS-670 polymorphism.…”

Section: Fas-670 Gene Polymorphism and Cervical Carcinogenesis Risk: mentioning

confidence: 93%

“…Among the eligible studies, 6 were conducted on Asian (13,24,25,27,28,30) and 4 on Caucasian populations (23,26,29,31). Two studies were classified as LSIL and HSIL (28,30) and one study included HSIL and cervical cancer (27), whereas others exclusively included cervical cancer patients (13,(23)(24)(25)(26)29,31).…”

Section: Identification and Characteristicsmentioning

confidence: 99%

See 1 more Smart Citation

FAS-670 gene polymorphism and cervical carcinogenesis risk: A meta-analysis

Huang

Wang

2013

Biomedical Reports

View full text Add to dashboard Cite

Abstract. FAS is a cell surface receptor that plays an important role in the etiology of cancer. Previous studies on the association between FAS-670 polymorphism and cervical carcinogenesis failed to reach a consensus; therefore, this meta-analysis was conducted to estimate the association of FAS-670 polymorphism and the risk of cervical cancer. This meta-analysis included 10 studies on FAS-670 genotyping, including a total of 2,901 cases and 2,831 controls. The complete overdominant model was applied in our meta- 2 =23.5%, P heterogeneity =0.03), whereas for Caucasians, no significant association was observed between FAS-670 polymorphism and cervical carcinogenesis (4 comparisons, OR=0.96, 95% CI: 0.75-1.24, I 2 =45.9%, P heterogeneity =0.14).

show abstract

Fas gene promoter −670 polymorphism (A/G) is associated with cervical carcinogenesis

Cited by 43 publications

References 18 publications

Polymorphisms of FAS and FAS Ligand Genes Involved in the Death Pathway and Risk and Progression of Squamous Cell Carcinoma of the Head and Neck

Polymorphisms of FAS and FAS Ligand Genes Involved in the Death Pathway and Risk and Progression of Squamous Cell Carcinoma of the Head and Neck

Lack of association between the FAS/FASL polymorphisms and cervical cancer risk: A meta-analysis

FAS-670 gene polymorphism and cervical carcinogenesis risk: A meta-analysis

Contact Info

Product

Resources

About